A Drug Utilization Study of Xofigo Use in Sweden

Trial Profile

A Drug Utilization Study of Xofigo Use in Sweden

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 24 Nov 2017

At a glance

  • Drugs Radium 223 chloride (Primary)
  • Indications Bone metastases; Prostate cancer
  • Focus Therapeutic Use
  • Sponsors Bayer
  • Most Recent Events

    • 14 Mar 2016 Planned End Date changed from 1 Jun 2016 to 1 Dec 2017, according to ClinicalTrials.gov record.
    • 14 Mar 2016 Planned primary completion date changed from 1 Jun 2016 to 1 Dec 2017, according to ClinicalTrials.gov record.
    • 11 Feb 2016 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top